

TABLE OF CONTENTS

March 3, 2008

No. 2080

BUSINESS

- 1 Daiichi Sankyo Places Top Priority on 5 Projects
- First Big Step on Road to a "Global Pharma Innovator"
- DU-176b Dose-Dependently Inhibits VTE
- Rivoglitazone More Effective in Reducing HbA1c than Pioglitazone
- Prasugrel Given First-Track Status in US
- 4 Toyobo Expands Contract Manufacturing Business
- 5 Sales of Plavix Up 5.5-Fold in Japan: sanofi-aventis
- 5 Competition Heats Up on the Market for Statins
- 6 Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
- Toho to Keep Stocks of 700 Generics from 4 Makers
- 7 Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
- 7 Number of Privately-Operated Pharmacies to be Halved: Mr Urushibata
- 7 **BUSINESS NEWS IN BRIEF**
- Sanofi Pasteur's ActHIB to Reach Japanese Children in Summer
- IBL to Commercialize Water-Soluble Creatine Globally

GENERICS

- 8 Pharmacies Will Lose or Win Depending on How Many Generics They Dispense
- 8 50-60% of People Want to Use Generics: Survey
- 9 Generics Will Be Dispensed for No More Than 10% of Prescriptions: Dr Muto
- 10 **Commentary**
- Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
- 9 **TOPICS**
- Daiichi Sankyo Introduces Stock Compensation-Type Stock Option Plan

SPONSOR FEATURE

- 11 Japan's Most Admired Pharma Companies in 2007: P. Reed Maurer

R&D

- 12 Fusion of Technologies from FUJIFILM and Toyama to Enhance R&D
- 12 PIII Trial of Nexavar in NSCLC Discontinued: Bayer, Onyx
- 13 Takeda, Merck Serono Drop Matuzumab due to Inefficacy
- 13 Negative Opinions Include Fear of Clinical Tri-

als: CMIC

- 14 Sanofi-aventis Enters into Antibody Agreements with Dyax
- 14 NCCHD-Led NW to Participate in Multinational Clinical Trials
- 15 Development Delayed for 16 Unapproved Drugs
- 16 Introduce GCP Auditor Certification System: Prof. Horie
- 16 *Koroshio* to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells

REGULATORY

- 17 Daiichi Sankyo, Eli Lilly Apply for Prasugrel in EU
- 17 New GL on Drugs Obtained from Autologous Cells Announced
- 17 Rate of Death due to Liver Cancer Is Third Highest in Japan
- 18 Japan Needs to Introduce Medicoeconomic Assessment of Medical Technologies: Prof Kamae
- 18 **REGULATORY NEWS IN BRIEF**
- JPMa Creates Taskforce on NHI Drug Pricing System Reform
- OPC-67683, CC-5013 Lenalidomide Designated as Orphan Drugs
- Lenalidomide Receives Orphan Drug Status: Celgene

SELF-MEDICATION

- 19 **Commentary**
- Preparations for New OTC Drug Marketing System Enter Final Stage

MEDICAL DEVICES

- 20 Need to Enhance R&D Ability of Medical Devices Industry Stressed

MEDICAL FACILITIES & NURSING CARE

- 20 NPhA Frustrated with Maintenance of 2 Different Dispensing Fees
- 21 Study on Inhibition of Diabetic Progression to Start this Year
- 21 Annual Limit of 25 Cases Proposed for CV Surgery Facilities
- 22 Real Medical Institution Bankruptcy Crisis Yet to Come
- 22 **TOPICS**
- Pfizer Foundation Supports 2 Japanese NGOs to Fight Tobacco and Breast Cancer
- 23 **Survey**
- Blood Pressure Management Not Adequate: Pfizer Survey
- Japanese Understanding of Antihistamines Inadequate: Pollinosis Survey